Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes

Manon Desmares , Marion Delphin (1, 2) , Brieux Chardès , Caroline Pons (2) , Juliette Riedinger , Maud Michelet (1) , Michel Rivoire (3, 4) , Bernard Verrier (5) , Anna Salvetti (2, 1) , Julie Lucifora (1) , David Durantel (2)

1 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
2 CIRI - Centre International de Recherche en Infectiologie
3 Centre Léon Bérard [Lyon]
4 Université de Lyon - UDL
5 LBTI - Laboratoire de Biologie Tissulaire et d'ingénierie Thérapeutique UMR 5305

Electronic word count (without references and figures legends): 6360 Number of figures: 6 Number of supplementary figures: 14 Competing financial interest none Revised Manuscript-Clear version (Will be published) Click here to view linked References

Domaines: Virologie

Manon Desmares, Marion Delphin, Brieux Chardès, Caroline Pons, Juliette Riedinger, et al.. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes. Antiviral Research, 2022, 206, pp.105386. ⟨10.1016/j.antiviral.2022.105386⟩. ⟨hal-03869860⟩